4-methylthioamphetamine

4-Methylthioamphetamine (4-MTA) is a designer drug and amphetamine derivative. It was developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a highly potent serotonin releasing agent (SRA) and is known for its psychoactive effects.

Chemistry[edit | edit source]

4-MTA belongs to the amphetamine class of psychoactive substances. It is structurally related to amphetamine itself, but the alpha-methyl group of amphetamine is replaced by a methylthio group in 4-MTA.

Pharmacology[edit | edit source]

4-MTA acts primarily as a serotonin releasing agent (SRA). It is known to increase the release of serotonin in the brain, leading to heightened serotonin levels. This results in the drug's psychoactive effects, which include feelings of euphoria, increased sociability, and altered perception.

Effects[edit | edit source]

The effects of 4-MTA can vary greatly depending on the dose and individual's physiology. Common effects include euphoria, increased sociability, and altered perception. However, high doses or prolonged use can lead to more serious side effects, such as anxiety, paranoia, and potentially dangerous increases in heart rate and blood pressure.

Legal Status[edit | edit source]

4-MTA is classified as a Schedule I controlled substance in the United States, meaning it is illegal to manufacture, distribute, or possess without a license. It is also controlled under similar laws in many other countries.